QUEEN MARY UNIVERSITY OF LONDON

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1882-01-08

Employees: 1K

Market Cap: -

Website: http://www.qmul.ac.uk

Clinical Trials

The Effects of C-type Natriuretic Peptide on Human Forearm Blood Vessels

Not Applicable

Withdrawn

Conditions: Ischaemia-reperfusion (IR) Injury

Interventions: Drug: C-type natriuretic peptide (CNP)
Drug: Saline
Drug: Acetylcholine

First Posted Date: 2010-02-25

Last Posted Date: 2020-05-05

Lead Sponsor: Queen Mary University of London

Registration Number: NCT01075776

Locations: 🇬🇧
Queen Mary University London, London, United Kingdom

A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium

Phase 2

Conditions: Bladder Cancer

Interventions: Drug: lapatinib ditosylate
Other: Placebo

First Posted Date: 2009-07-30

Last Posted Date: 2015-04-15

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 204

Registration Number: NCT00949455

Locations: 🇬🇧
Barts and the London NHS Trust, London, England, United Kingdom
🇬🇧
Mid Essex NHS Trust - Broomfield Hospital, Chelmsford, United Kingdom
🇬🇧
Cambridge University Hospitals NHS Trust - Addenbrooke's Hospital, Cambridge, United Kingdom

and more 24 locations

Study of Biomarkers in Blood and/or Tumor Tissue Samples From Patients With Ductal Carcinoma in Situ and From Healthy Volunteers

Conditions: Breast Cancer

First Posted Date: 2009-07-08

Last Posted Date: 2013-08-12

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 6000

Registration Number: NCT00935233

Locations: 🇬🇧
North Devon District Hospital, Barnstaple, England, United Kingdom
🇬🇧
Colchester General Hospital, Colchester, England, United Kingdom
🇬🇧
Helen Rollason Cancer Care Centre at North Middlesex Hospital, London, England, United Kingdom

and more 15 locations

Use of Varenicline for 4-weeks Prior to Quitting

Phase 3

Completed

Conditions: Tobacco Dependence
Smoking Cessation

Interventions: Drug: Varenicline
Drug: Placebo

First Posted Date: 2008-11-11

Last Posted Date: 2013-12-12

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 101

Registration Number: NCT00789074

Locations: 🇬🇧
Tobacco Dependence Research and Treatment Unit, London, United Kingdom

Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial

Not Applicable

Terminated

Conditions: Ulcerative Colitis

Interventions: Behavioral: Gut focussed hypnotherapy
Behavioral: Control educational sessions

First Posted Date: 2007-11-04

Last Posted Date: 2019-06-28

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 26

Registration Number: NCT00553163

Locations: 🇬🇧
Barts and The Royal London NHS Trust/Queen Mary University London/, London, United Kingdom
🇬🇧
University College Hospital London, London, United Kingdom
🇬🇧
Guy's and St Thomas' NHS Trust, London, United Kingdom

Anterior Perineal Plane for Ultra Low Anterior Resection of the Rectum

Not Applicable

Completed

Conditions: Rectal Neoplasms
Colitis, Ischemic
Colitis, Ulcerative

Interventions: Procedure: Proctectomy
Procedure: Standard abdominal approach for rectal excision
Procedure: APPEAR Procedure

First Posted Date: 2007-09-24

Last Posted Date: 2023-03-01

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 23

Registration Number: NCT00534131

Locations: 🇬🇧
Centre For Academic Surgery, The Royal London Hospital, London, England, United Kingdom

Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

First Posted Date: 2007-02-27

Last Posted Date: 2007-02-27

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 256

Registration Number: NCT00440687

Locations: 🇬🇧
Centre for Health Sciences, Queen Mary's School of Medicine and Dentistry, Barts and The London, 2 Newark Street,., London and Essex, London, United Kingdom

Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles

Phase 3

Completed

Conditions: Testicular Germ Cell Tumor
Drug/Agent Toxicity by Tissue/Organ

First Posted Date: 2006-05-11

Last Posted Date: 2013-08-12

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 210

Registration Number: NCT00324298

Locations: 🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom
🇬🇧
University College of London Hospitals, London, England, United Kingdom
🇬🇧
Ipswich Hospital, Ipswich, England, United Kingdom

and more 7 locations

Tamoxifen for the Prevention of Breast Cancer in High-Risk Women

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen Citrate 20Mg Tab
Other: Placebo

First Posted Date: 2004-05-11

Last Posted Date: 2024-12-11

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 7154

Registration Number: NCT00002644

Locations: 🇬🇧
Queen Mary University of London, London, England, United Kingdom

Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: placebo
Drug: anastrozole

First Posted Date: 2004-03-09

Last Posted Date: 2021-10-06

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 3864

Registration Number: NCT00078832

Locations: 🇫🇮
Pirkanmaa Cancer Society, Tampere, Finland
🇲🇹
Sir Paul Boffa Hospital, Harper Lane, Floriana, Malta
🇨🇭
Inselspital Bern, Bern, Switzerland

and more 70 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy